

How to Run the Object 3125 Report in Quantum Analytics

Object 3125 is the Expense Object used to record study participant payment (SPP) cash and gift cards payments that have been distributed to participants.

1. Log into Quantum Analytics.



Need access to Quantum Analytics? Complete the Access Request Form.

2. Click Award Detail on the Quantum Analytics Landing Page:

Sponsored Management

Trends Analyze year-over-year trends of sponsored proposals, awards and expenditures on a fiscal year basis. Includes graphical and tabular displays of the data.

Search

Identify Quantum awards and Quantum projects meeting various criteria. HINT: To search Kuali Research proposals and awards utilize the Kuali download pages on the download dashboard.

PI Profile

Provides a one-stop shop to provide information on the entire sponsored portfolio of an individual Principal Investigator. Drillable to Award Detail for a deeper analysis of each award.

Award Detail Comprehensive details necessary to manage an individual award or project includes budget to actual as well as various reports of revenue and expense activity on an inception-lo-date basis.

Find My Award

Having trouble finding your Award Number but you know other attributes like the Project Number, PI, Owning Organization, and Sponsor? Use this page to more quickly identify Awards.

F&A Yield

Displays "F&A Yield" – a calculation of the yield of the effective indirect cost rate, expressed as a percentage of total direct costs. Page provides users the option to see the results either with or without Cost Share.

SPP 7062 Activity

Disflays all study participant payment (SPP) activity processed through Object 7062 (Cash Study Participant Pay), including the Initial issuance of the working fund check and the debit memo charges to Object 3125 (Participant Study Pay Group) reflecting distributions to participants. Drillable to NONPO invoice and debit memo defails.



3. Select the Award or click Find my Award:

| | QA4 | Sp | onsored | Man | agement |
|---------------------|-----------------|----|---------------|-------|--------------|
| QA4.P1 - Trends | QA4.P2 - Search | Q/ | \4.P3 - PI Pr | ofile | QA4.P4 - Awa |
| Landing Page | | | Plea | ise | select |
| * Award | | | Note | e: I | f you're l |
| Select Value | - | | | | |
| Exclude Cos | t Sharing | | | | |
| * Thru Fiscal Ye | ar | | | | |
| 2021 | • | | | | |
| * Thru Fiscal Pe | eriod | | | | |
| Select Value | • | | | | |
| | Apply Reset | • | | | |
| Having trouble find | ing your award? | | | | |
| Find My Award | | | | | |

If Find My Award is selected, enter the Project ID on the next page. Otherwise advance to Step 4.



QA4 - Sponsored Management

QA4.P1 - Trends QA4.P2 - Search QA4.P3 - PI Profile QA4.P4 - Award Detail QA4.P5 - Find My Award QA4.P6 - F&A Yield QA4.P7 - 7062 Activity

Landing Page

(QA4.P5.R1) What is my Award Number and Name?

| Award Owning School | Project Owning School | | | | | | | | |
|-------------------------|---------------------------|--|--|--|--|--|--|--|--|
| (All Column Value: | (All Column Value: | Quantum Award | | | | | | | |
| | | 000073-EVAL OF PROTECTIVE DISEASE ASSOC THERAPEUTIC IMMUNITY HE | | | | | | | |
| Award Owning Department | Project Owning Department | 000084C-Intestinal mucosal growth in health and surgical disease | | | | | | | |
| (All Column Value: | (All Column Value:▼ | 000803A-Effects Exercise Endothelial Function in Stroke Patients | | | | | | | |
| Award Owning Org | Project Owning Org | 000918E-Neuroinflammation, Epigenetics and Male Vulnerability | | | | | | | |
| (All Column Value: | (All Column Value: | 010254E-Oligonucleotide Conformational Heterogeneity | | | | | | | |
| Sponsor Number | Droject DI | 010500C-p38MAP kinase-dependent mechanisms of fever-enhanced acu | | | | | | | |
| (All Caluma Malua | | 010636G-CRIC III (Year 8) | | | | | | | |
| (All Column value: | Select value | 010636H-CRIC IV PY2 | | | | | | | |
| Sponsor Name | Project Number | 010649E-BCPS FY18 Judy Center MOU | | | | | | | |
| (All Column Value: | 30014901 👻 | 010649F-BCPS FY19 Judy Center | | | | | | | |
| Award PI | Project Name | 010649G-BCPS FY20 Judy Center | | | | | | | |
| Select Value | (All Column Value: | 010692C-Cognitive Neuroscience of Attention and Working Memory i | | | | | | | |
| | | 010692E-Cognitive Neuroscience of Attention and Working Memory i | | | | | | | |
| | Quantum | 020193C-MUCOSAL REPAIR IN GUT SURGICAL | | | | | | | |
| | Apply Reset V | 020384G-Ryan White Part B Oral Health (Dental School PLUS Pro 020384H-Ryan White Part B Oral Health (Dental School PLUS Pro | | | | | | | |
| | | | | | | | | | |
| | | 020468D-Cochrane Complementary Medicine Field: Resource for Rese | | | | | | | |
| | | 2005405 Usersta Ostational An Distance with ADD (UODWA) | | | | | | | |

4. Select the Award and then click Drill to Detail Transactions when prompted.



5. Enter Thru Fiscal Period and Click Apply:

| | LYTICS | QA4 - | Sponsored Mar | agement | |
|--|-----------------------------------|----------------|---------------------|-----------------------|------------------------|
| QA4.P1 - Trends | QA4.P2 | - Search | QA4.P3 - PI Profile | QA4.P4 - Award Detail | QA4.P5 - Find My Award |
| Landing Page | | | Please | select an Av | vard, Thru Fis |
| * Award | | | Note. I | i you'le naving | |
| 3001490-CCT 4 | 361-20 A I | Phase 🗸 | | | |
| Thru Fiscal Ye 2021 Thru Fiscal Pe | ear • • • • • • | | | | |
| Apr | • | | | | |
| | Apply | Reset v | | | |
| Having trouble find | ling your a | ward? | | | |
| Find My Award | | | | | |
| | | | | | |



4

ADMINISTRATION AND FINANCE

6. Click the LTD (Life-to-Date) Operating Expenses:

| QA4.P1 - Trends QA4.P2 - Search QA4.F | P3 - PI Prolite | QA4.P5 - P | ind My Award C | IA4.P0 - F6A field QA4. | 7 - 7062 Activity | | | | | | |
|--|---|---------------------------|----------------|-------------------------|------------------------|--------------|----------------------|------------------------|-----------|--|--|
| Fiscal Period Year is equal to 2021 | | | | | | 1 | LTD Miscellaneou | is Revenue: | \$0.0 | | |
| and Fiscal Month Name is equal to Apr | | | | | | | | | | | |
| to 3001490-CCT 4361-20 A Phase 3. | | | | | | | LTD Costs: | | | | |
| Randomized, Double-Blind, Placebo- Controlled Study Assessing the Efficacy and Safety of Anti-Spike | | | | | | (LTD Bille | d - LTD Costs) + LTD | Miscellaneous Revenue: | \$25,891. | | |
| SARS-CoV-2 Monoclonal Antibodies in | | | | | | | | | | | |
| and Exclude Cost Share Flag is equal to | | Time run: 4/22/2024 P:12 | a Commitme | nts summary for tr | is Award/Project? (C | (A4.P4.R11 |) | | | | |
| Exclude Cost Sharing | Exclude Cost Sharing I is equal to Time run: 4/22/2021 8:12:54 AM | | | | | | | | | | |
| | | | | Ву | Object • | | | | | | |
| Having trouble finding your award? | | | | | | | | | | | |
| Find My Award | | Object Level B | Cost Structure | Object Level C | Period Activity Amount | LTD Costs | Raw Commitments | Projected Total Cost | | | |
| Additional Expetionality New | | B100~Direct Costs | TDC | C100~Salaries | \$9,750.14 | \$55,721.29 | \$99,185.20 | \$154,906.49 | | | |
| Available: | | | | C200~Fringe Benefits | \$3,157.26 | \$19,001.97 | \$30,091.26 | \$49,093.23 | | | |
| New Report: What is the activity on the 7062 & 7072 Cash Been On This | | | | C300~Operating Expense | s \$3,000.00 | \$23,702.02 | \$0.00 | \$23,702.02 | | | |
| Award/Project? | | | TDC Total | | \$15,907.40 | \$98,425.28 | \$129,276.46 | \$227,701.74 | | | |
| Award Detail (this page): | | | Non-TDC | C300~Operating Expense | s \$0.00 | \$1,300.00 | \$0.00 | \$1,300.00 | | | |
| | | | Non-TDC Total | | \$0.00 | \$1,300.00 | \$0.00 | \$1,300.00 | | | |
| Report Folostor | | B100~Direct Costs Total | | | \$15,907.40 | \$99,725.28 | \$129,276.46 | \$229,001.74 | | | |
| What Are The POs and PRs On This Av | vard? | B600~InDirect Costs | F&A | C600~Indirect Costs | \$4,772.25 | \$29,527.69 | \$0.00 | \$29,527.69 | | | |
| Who Is This Award/Project Funding? What Is The History Of Funding On This Award? What Has Been Billed And Collected On This Award? | | | F&A Total | | \$4,772.25 | \$29,527.69 | \$0.00 | \$29,527.69 | | | |
| | | B600~InDirect Costs Total | | | \$4,772.25 | \$29,527.69 | \$0.00 | \$29,527.69 | | | |
| O What is the activity on the 7062 & 7072 | Cash Been On Tr | Grand Total | | | \$20,679.65 | \$129,252.97 | \$129,276.46 | \$258,529.43 | | | |
| 1 | | | | | | | | | | | |

7. Find the Period Selection Area and select a range of periods:

| Thru Apr-21 (Fiscal Year: 2021 - Fiscal Month: Apr) Award Number: 3001490 | Where Are My Expenses Coming From? (QA4.P4.D4.R2) Run by: Cynthia Lyons Time run: 4/22/2021 8:15:24 AM | | | | |
|--|---|----------------|-------------------------------|--|--|
| has \$25,002.02 of Life-to-Date Expenses in Quantum | Transaction Type | Amount | | | |
| Financials | R01-Debit Memo | \$6,500.00 | | | |
| based on the following filters: | R03-Check Request / Working Fund | \$17,000.00 | | | |
| Distortion The New Section 2010 1990 1990 1990 1990 1990 1990 1990 | R04.A-Pcard Expense | \$202.02 | | | |
| and Object Level A Code. Description is equal to / sin A 100-Expresses | R13-SPAC Adjustment Entries | \$0.00 | | | |
| and Flocal Period Year is equal to 2021 | Grand Total | \$23,702.02 | | | |
| and Production from a fequel to Apple and Decision of the Program | Quantum Avard Number is equal to 3004401 and Object Level A Code - Description is equal to 1's in A100-Expenses and Object Level B Code - Description is equal to 1's in B100-Direct Costs and Object Level C Code - Description is equal to 1's in 500-Operating Expense and Project Number is equal to 30044901 and "Dim A1 To Unions" Prior End C* - « (Imsettam 2021-04-30 00:00 00) | | | | |
| | and Exclude Cost Share Flag is equal to and Actuals is equal to / is in Actuals | any Exclude Co | st Share Flag in 🙆 QA4.P4.R10 | | |

What Timeframe Matters to You? O Show Transactions for Period Activity Show Transactions for Range of Periods

8. Enter the range of periods and click Apply:

What Timeframe Matters to You? O Show Transactions for Period Activity

Show Transactions for Range of Periods

Fiscal Year 2021 ▼ Fiscal Period Beg >= JUL-20 ▼ Fiscal Period End <= APR-21 ▼ CExclude Cost Sharing Apply Reset ▼

9. The results show the amount charged (i.e. distributed) for the period(s) being reconciled.

Fiscal Year 2021 V Fiscal Period Beg >= JUL-20 V Fiscal Period End <= APR-21 V Zeclude Cost Sharing Apply Reset V

Show Me All of My Transactions on Award 3001490 for the range of periods (QA4.P4.D3.R4)

View By Pivot Table 🔻

| | | | | | | 2021 | | | | | Amount | | | | | | |
|-------------------------------------|-------------|------------------------------|----------|-----------------|--|---|--|----------------------------------|-----------|---|----------------------------------|------------|------------|----------|--|--|----------|
| | | | | | | | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 | | | | | | |
| Object Level C | Object Code | Object Description | Project | Document Number | Line Item Details | Transaction Type | Amount | Amount | Amount | Amount | Amount | | | | | | |
| C300-Operating Expenses 3 3 3 | 3125 | Participant Study Pay- Group | 30014901 | 21-SK0175A | 2 - 21-SK0175A Study participants have been compensated (10/22-12/15/20) | R01-Debit Memo | | \$6,000.00 | | | | \$6,000.00 | | | | | |
| | | | | 21-SK0294A | 2 - 21-SK0294A Study participants have been compensated (12/4/20-3/17/21 | R01-Debit Memo | | | | \$500.00 | | \$500.00 | | | | | |
| | | | 30014901 | 30014901 Total | | | | | | \$500.00 | | \$6,500.00 | | | | | |
| | 3125 Total | | | | | | | \$6,000.00 | | \$500.00 | | \$6,500.00 | | | | | |
| | 3130 | Participant Study Pay- Indiv | 30014901 | 21-SK0194 | 1 - 21-SK0194 Compensation for Regeneron Study | R03-Check Request / Working Fund | \$250.00 | | | | | \$250.00 | | | | | |
| | | | | 21-SK0195 | 1 - 21-SK0195 Compensation for Regeneron Study | R03-Check Request / Working Fund | \$250.00 | | | | | \$250.00 | | | | | |
| | | | | | | | | | 21-SK0196 | 1 - 21- SK0196 Compensation for Regeneron Study | R03-Check Request / Working Fund | \$250.00 | | | | | \$250.00 |
| | | | | | | 21-SK0197 | 1 - 21-SK0197 Compensation for Regeneron Study | R03-Check Request / Working Fund | \$250.00 | | | | | \$250.00 | | | |
| | | | | | 21-SK0214 | 6 - 21-SK2014 WFC required for Regeneron study compensation | R03-Check Request / Working Fund | \$1,000.00 | | | | | \$1,000.00 | | | | |
| | | | | | 21-SK0215 | 6 - 21-SK0215 WFC required for Regeneron study compensation | R03-Check Request / Working Fund | \$1,000.00 | | | | | \$1,000.00 | | | | |
| | | | | | | | | | | | | | | | | | |

Please select Fiscal Year and Fiscal Period in the above dashboard prompt to view Period Range Activity Transactions for the Award (QA4.P4.D3.R4) Refresh